Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 17401
Country/Region: Lesotho
Year: 2016
Main Partner: Elizabeth Glaser Pediatric AIDS Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $6,597,181 Additional Pipeline Funding: $1,879,559

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $544,362
Care: TB/HIV (HVTB) $733,993
Care: Pediatric Care and Support (PDCS) $376,170
Testing: HIV Testing and Counseling (HVCT) $259,368
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $277,984
Treatment: Adult Treatment (HTXS) $3,739,370
Treatment: Pediatric Treatment (PDTX) $665,934
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 541
HTS_TST Age/sex: 1-9 2017 10,663
HTS_TST Age/sex: 10-14 Female 2017 3,503
HTS_TST Age/sex: 10-14 Male 2017 3,366
HTS_TST Age/sex: 15-19 Female 2017 3,986
HTS_TST Age/sex: 15-19 Male 2017 2,445
HTS_TST Age/sex: 20-24 Female 2017 12,154
HTS_TST Age/sex: 20-24 Male 2017 7,139
HTS_TST Age/sex: 25-49 Female 2017 89,187
HTS_TST Age/sex: 25-49 Male 2017 67,282
HTS_TST Age/sex: 50+ Female 2017 20,579
HTS_TST Age/sex: 50+ Male 2017 11,573
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 232,418
HTS_TST Service Delivery Point (Facility): Inpatient 2017 2,320
HTS_TST Service Delivery Point (Facility): Outpatient 2017 166,029
HTS_TST Service Delivery Point (Facility): Pediatric 2017 64,069
HTS_TST Sum of Age/Sex disaggregates 2017 221,214
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 144
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 144
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 530
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 323
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 1,614
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 947
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 11,853
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 8,940
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 2,733
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 1,540
HTS_TST_POS Test Result by Age: Positive: <1 2017 124
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 327
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,137
PMTCT_ART New on ART 2017 1,637
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 13,063
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 2,082
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 694
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 8
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 55
PMTCT_EID Sum of Infant Age disaggregates 2017 2,776
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 132
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 2,743
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 4,312
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 5,877
PMTCT_STAT By: Known positives at entry 2017 1,798
PMTCT_STAT By: Number of new positives identified 2017 1,122
PMTCT_STAT Number of new ANC and L&D clients 2017 13,753
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 13,063
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 11
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 376
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 595
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 815
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: <15 2017 3
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 233
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 375
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 504
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,920
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 137
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 2,889
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 4,542
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 6,186
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 122
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,063
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 181
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,577
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 2,941
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 2,941
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 3,378
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 3,378
TB_SCREENDX Screen Result: Screened Positive for TB 2017 3,378
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 41,373
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 22,283
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 2,009
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 1,934
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 67,598
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 181
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,588
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 260
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,378
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 4,407
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 4,407
TX_CURR Age/Sex: <1 2017 124
TX_CURR Age/Sex: <1-9 2017 2,447
TX_CURR Age/Sex: 10-14 Female 2017 803
TX_CURR Age/Sex: 10-14 Male 2017 770
TX_CURR Age/Sex: 15-19 Female 2017 1,247
TX_CURR Age/Sex: 15-19 Male 2017 765
TX_CURR Age/Sex: 20-24 Female 2017 3,802
TX_CURR Age/Sex: 20-24 Male 2017 2,230
TX_CURR Age/Sex: 25-49 Female 2017 27,884
TX_CURR Age/Sex: 25-49 Male 2017 21,034
TX_CURR Age/Sex: 50+ Female 2017 6,434
TX_CURR Age/Sex: 50+ Male 2017 3,619
TX_CURR Aggregated Age/Sex: <15 Female 2017 2,111
TX_CURR Aggregated Age/Sex: <15 Male 2017 2,034
TX_CURR Aggregated Age/Sex: 15+ Female 2017 39,367
TX_CURR Aggregated Age/Sex: 15+ Male 2017 27,647
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 71,158
TX_CURR Sum of age/sex disaggregates 2017 2,012
TX_CURR Sum of Aggregated Age/Sex <15 2017 4,145
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 67,014
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 71,159
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1,224
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 1,197
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 16,778
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 11,773
TX_NEW By Age/Sex: <1 2017 80
TX_NEW By Age/Sex: 1-9 2017 1,425
TX_NEW By Age/Sex: 10-14 Female 2017 471
TX_NEW By Age/Sex: 10-14 Male 2017 452
TX_NEW By Age/Sex: 15-19 Female 2017 529
TX_NEW By Age/Sex: 15-19 Male 2017 328
TX_NEW By Age/Sex: 20-24 Female 2017 1,619
TX_NEW By Age/Sex: 20-24 Male 2017 948
TX_NEW By Age/Sex: 25-49 Female 2017 11,881
TX_NEW By Age/Sex: 25-49 Male 2017 8,963
TX_NEW By Age/Sex: 50+ Female 2017 2,743
TX_NEW By Age/Sex: 50+ Male 2017 1,533
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 30,972
TX_NEW Sum of Age/Sex disaggregates 2017 29,467
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 30,972
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 64,038
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 57,637
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,711
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 1,645
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 35,279
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 19,003
TX_PVLS Numerator: Indication: Routine 2017 57,637
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,904
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,827
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 39,196
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 21,111
TX_PVLS_den Denominator: Indication: Routine 2017 64,038
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 226
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,375
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 392
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 373
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 370
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 100
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,921
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 305
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,360
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,710
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,224
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,020
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,177
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,310
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 9,755
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,134
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 18,376
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 22,404
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 272
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,530
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 473
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 455
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 456
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 115
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,343
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 376
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,889
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,747
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,501
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,244
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,365
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,365
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12,192
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,482
Cross Cutting Budget Categories and Known Amounts Total: $670,000
Human Resources for Health $150,000
Food and Nutrition: Policy, Tools, and Service Delivery $50,000
Gender: Gender Based Violence (GBV) $150,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Gender: Gender Equality $120,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Water $200,000